Recent News

• 09.15.2025 - Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
• 08.28.2025 - Can-Fite Reports H1 2025 Financial Results and Clinical Update
• 07.30.2025 - Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
• 07.28.2025 - Can-Fite Announces Up To $15.0 Million Public Offering
• 07.28.2025 - Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia

Recent Filings

• 09.11.2025 - EFFECT Notice of Effectiveness
• 09.11.2025 - EFFECT Notice of Effectiveness
• 09.08.2025 - POS AM Post-Effective amendments for registration statement
• 09.08.2025 - POS AM Post-Effective amendments for registration statement
• 09.08.2025 - POS AM Post-Effective amendments for registration statement
• 09.08.2025 - POS AM Post-Effective amendments for registration statement
• 08.28.2025 - POS AM Post-Effective amendments for registration statement
• 08.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.28.2025 - POS AM Post-Effective amendments for registration statement
• 08.28.2025 - EX-99.1 EX-99.1